Alterations in lipid kinetics in men with HIV-dyslipidemia

American Journal of Physiology - Endocrinology and Metabolism

Volumn 285, Issue 3 48-3, 2003, Pages

  Reeds, D N ^a   Mittendorfer, B ^a   Patterson, B W ^a   Powderly, W G ^a   Yarasheski, K E ^a   Klein, S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Human immunodeficiency virus; Hypertriglyceridemia; Lipolysis; Metabolism; Stable isotopes

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CORONARY RISK; DYSLIPIDEMIA; FATTY ACID TRANSPORT; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPOLYSIS; MALE; PLASMA CLEARANCE; PRIORITY JOURNAL;

EID: 0042466401     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00118.2003     Document Type: Article

References (50)

1. Aarsland A, Chinkes D, and Wolfe RR. Contributions of de novo synthesis of fatty acids to total VLDL-triglyceride secretion during prolonged hyperglycemia/hyperinsulinemia in normal man. J Clin Invest 98: 2008-2017, 1996.
2. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann Med 27: 435-438, 1995.
3. Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol 14, Suppl B: 14B-17B, 1998.
4. Baril L, Beucler I, Valantin MA, Bruckert E, Bonnefont-Rousselot D, Coutellier A, Caumes E, Katlama C, and Bricaire F. Low lipolytic enzyme activity in patients with severe hypertriglyceridemia on highly active antiretroviral therapy. AIDS 15: 415-417, 2001.
5. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M, and Schmidt RE. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63-F70, 1999.
6. Bergman RN, Van Citters GW, Mittelman SD, Dea MK, Hamilton-Wessler M, Kim SP, and Ellmerer M. Central role of the adipocyte in the metabolic syndrome. J Investig Med 49: 119-126, 2001.
7. Boer P. Estimated lean body mass as an index for normalization of body fluid volumes in humans. Am J Physiol Renal Fluid Electrolyte Physiol 247: F632-F636, 1984.
8. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, and Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58, 1998.
9. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, and Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353: 2093-2099, 1999.
10. Castelli WP. Cholesterol and lipids in the risk of coronary artery disease: the Framingham Heart Study. Can J Cardiol 4, Suppl A: 5A-10A, 1988.
11. Converse CA and Skinner ER. Lipoprotein Analysis: A Practical Approach. New York: Oxford Univ. Press, 1992.
12. Egusa G, Beltz WF, Grundy SM, and Howard BV. Influence of obesity on the metabolism of apolipoprotein B in humans. J Clin Invest 76: 596-603, 1985.
13. Groop LC, Bonadonna RC, Simonson DC, Petrides AS, Shank M, and DeFronzo RA. Effect of insulin on oxidative and nonoxidative pathways of free fatty acid metabolism in human obesity. Am J Physiol Endocrinol Metab 263: E79-E84, 1992.
14. Grunfeld C, Kotler DP, Hamadeh R, Tierney A, Wang J, and Pierson RN. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 86: 27-31, 1989.
15. Hadigan C, Borgonha S, Rabe J, Young V, and Grinspoon S. Increased rates of lipolysis among human immunodeficiency virus-infected men receiving highly active antiretroviral therapy. Metabolism 51: 1143-1147, 2002.
16. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, Davis B, Sax P, Stanley T, Wilson PW, D'Agostino RB, and Grinspoon S. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32: 130-139, 2001.
17. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, and Grinspoon S. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 84: 1932-1937, 1999.
18. Hadigan C, Rabe J, Meininger G, Aliabadi N, Breu J, and Grinspoon S. Inhibition of lipolysis improves insulin sensitivity in protease inhibitor-treated HIV-infected men with fat redistribution. Am J Clin Nutr 77: 490-494, 2003.
19. Hales CN and Randle PJ. Immunoassay of insulin with insulin antibody precipitate. Biochem J 88: 137-146, 1963.
20. Hellerstein MK, Grunfeld C, Wu K, Christiansen M, Kaempfer S, Kletke C, and Shackleton CH. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 76: 559-565, 1993.
21. Horowitz JF and Klein S. Whole body and abdominal lipolytic sensitivity to epinephrine is suppressed in upper body obese women. Am J Physiol Endocrinol Metab 278: E1144-E1152, 2000.
22. Hudgins LC, Hellerstein M, Seidman C, Neese R, Diakun J, and Hirsch J. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J Clin Invest 97: 2081-2091, 1996.
23. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, and Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24: 683-689, 2001.
24. Jensen MD and Heiling VJ. Heated hand vein blood is satisfactory for measurements during free fatty acid kinetic studies. Metabolism 40: 406-409, 1991.
25. Klein S and Wolfe RR. Whole-body lipolysis and triglyceride-fatty acid cycling in cachectic patients with esophageal cancer. J Clin Invest 86: 1403-1408, 1990.
26. Lamon-Fava S, Wilson PW, and Schaefer EJ. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler Thromb Vasc Biol 16: 1509-1515, 1996.
27. Lewis GF. Fatty acid regulation of very low density lipoprotein production. Curr Opin Lipidol 8: 146-156, 1997.
28. Lewis GF, Uffelman KD, Szeto LW, Weller B, and Steiner G. Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans. J Clin Invest 95: 158-166, 1995.
29. Liang JS, Distler O, Cooper DA, Jamil H, Deckelbaum RJ, Ginsberg HN, and Sturley SL. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nat Med 7: 1327-1331, 2001.
30. Martinez E, Conget I, Lozano L, Casamitjana R, and Gatell JM. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13: 805-810, 1999.
31. Meek SE, Nair KS, and Jensen MD. Insulin regulation of regional free fatty acid metabolism. Diabetes 48: 10-14, 1999.
32. Mittendorfer B, Horowitz JF, and Klein S. Gender differences in lipid and glucose kinetics during short-term fasting. Am J Physiol Endocrinol Metab 281: E1333-E1339, 2001.
33. Mittendorfer B, Patterson B, Klein S, and Sidossis L. VLDL-triglyceride kinetics during hyperglycemia-hyperinsulinemia: effects of sex and obesity. Am J Physiol Endocrinol Metab 284: E708-E715, 2003.
34. Patterson BW, Mittendorfer B, Elias N, Satyanarayana R, and Klein S. Use of stable isotopically labeled tracers to measure very low density lipoprotein-triglyceride turnover. J Lipid Res 43: 223-233, 2002.
35. Patterson BW, Zhao G, Elias N, Hachey DL, and Klein S. Validation of a new procedure to determine plasma fatty acid concentration and isotopic enrichment. J Lipid Res 40: 2118-2124, 1999.
36. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, and Mooser V. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100: 700-705, 1999.
37. Purnell JQ, Zambon A, Knopp RH, Pizzuti DJ, Achari R, Leonard JM, Locke C, and Brunzell JD. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 14: 51-57, 2000.
38. Ranganathan S and Kern PA. The HIV protease inhibitor saquinavir impairs lipid metabolism and glucose transport in cultured adipocytes. J Endocrinol 172: 155-162, 2002.
39. Reichl D. Lipoproteins of human peripheral lymph. Eur Heart J 11, Suppl E: 230-236, 1990.
40. Renard E, Fabre J, Paris F, Reynes J, and Bringer J. Syndrome of body fat redistribution in HIV-1-infected patients: relationships to cortisol and catecholamines. Clin Endocrinol (Oxf) 51: 223-230, 1999.
41. Richelsen B, Pedersen SB, Moller-Pedersen T, and Bak JF. Regional differences in triglyceride breakdown in human adipose tissue: effects of catecholamines, insulin, and prostaglandin E2. Metabolism 40: 990-996, 1991.
42. Schmitz M, Michl GM, Walli R, Bogner J, Bedynek A, Seidel D, Goebel FD, and Demant T. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. J Acquir Immune Defic Syndr Hum Retrovirol 26: 225-235, 2001.
43. Schwarz JM, Neese RA, Turner S, Dare D, and Hellerstein MK. Short-term alterations in carbohydrate energy intake in humans. Striking effects on hepatic glucose production, de novo lipogenesis, lipolysis, and whole-body fuel selection. J Clin Invest 96: 2735-2743, 1995.
44. Sekhar RV, Jahoor F, White AC, Pownall HJ, Visnegarwala F, Rodriguez-Barradas MC, Sharma M, Reeds PJ, and Balasubramanyam A. Metabolic basis of HIV-lipodystrophy syndrome. Am J Physiol Endocrinol Metab 283: E332-E337, 2002.
45. Sidossis LS, Mittendorfer B, Chinkes D, Walser E, and Wolfe RR. Effect of hyperglycemia-hyperinsulinemia on whole body and regional fatty acid metabolism. Am J Physiol Endocrinol Metab 276: E427-E434, 1999.
46. Steele R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82: 420-430, 1959.
47. Sutinen J, Hakkinen AM, Westerbacka J, Seppala-Lindroos A, Vekavaara S, Halavaara J, Jarvinen A, Ristola M, and Yki-Jarvinen H. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16: 2183-2193, 2002.
48. Van der Valk M, Bisschop PH, Romijn JA, Ackermans MT, Lange JM, Endert E, Reiss P, and Sauerwein HP. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15: 2093-2100, 2001.
49. Van der Valk M, Reiss P, van Leth FC, Ackermans MT, Endert E, Romijn JA, Heijligenberg R, and Sauerwein H. Highly active antiretroviral therapy-induced lipodystrophy has minor effects on human immunodeficiency virus-induced changes in lipolysis, but normalizes resting energy expenditure. J Clin Endocrinol Metab 87: 5066-5071, 2002.
50. Wolfe RR. Radioactive and Stable Isotope Tracers in Biomedicine: Principles and Practice of Kinetic Analysis. New York: Wiley-Liss, 1992.